The British pharmaceutical company AstraZeneca has claimed that the results of their trial testing a drug developed by them for the treatment of lung cancer are promising.
According to Reuters, the pharmaceutical company conducted a trial on a limited number of patients suffering from lung cancer using their prepared drug, Imfinzi.
During the trial, one group of patients was given the new drug while the other group was given a placebo, and then the progression of the disease was assessed.
It was found from the results that patients with lung cancer benefited from the administration of the new drug after chemotherapy, and their disease did not worsen.
The company claimed that patients who received the new drug remained healthy even after the trial and did not experience an exacerbation of the disease.
The company did not specify how many doses of the new vaccine were given to patients during the trial, but it was stated that the results of the limited trial were encouraging.
Now, the mentioned drug will undergo large-scale testing, followed by the final vaccine trial.
It should be noted that lung cancer, a common and dangerous cancer, affects individuals who typically live up to five years or more.
According to experts, lung cancer progresses rapidly even after chemotherapy and radiotherapy, and usually, up to 30 percent of diagnosed individuals live for five years after diagnosis.
